Astrazeneca (AZN) Other Gross PP&E Adjustments (2016 - 2026)

Astrazeneca has reported Other Gross PP&E Adjustments over the past 17 years, most recently at $11.3 billion for Q1 2026.

For Q1 2026, Other Gross PP&E Adjustments rose 21.06% year-over-year to $11.3 billion; the TTM value through Mar 2026 reached $11.3 billion, up 21.06%, while the annual FY2025 figure was $11.2 billion, 26.69% up from the prior year.
Other Gross PP&E Adjustments for Q1 2026 was $11.3 billion at Astrazeneca, up from $11.2 billion in the prior quarter.
Over five years, Other Gross PP&E Adjustments peaked at $11.3 billion in Q1 2026 and troughed at $7.5 billion in Q3 2022.
A 5-year average of $8.8 billion and a median of $8.3 billion in 2023 define the central range for Other Gross PP&E Adjustments.
On a YoY basis, Other Gross PP&E Adjustments climbed as much as 36.28% in 2022 and fell as far as 9.55% in 2022.
Year by year, Other Gross PP&E Adjustments stood at $7.6 billion in 2022, then rose by 9.74% to $8.3 billion in 2023, then grew by 6.69% to $8.9 billion in 2024, then grew by 26.69% to $11.2 billion in 2025, then increased by 0.71% to $11.3 billion in 2026.
Business Quant data shows Other Gross PP&E Adjustments for AZN at $11.3 billion in Q1 2026, $11.2 billion in Q4 2025, and $10.4 billion in Q3 2025.

Peer Comparison